Latest news

Thumbnail

J&J’s Stelara wins US nod for Crohn’s

US regulators have expanded the reach of Johnson & Johnson group Janssen Biologics' psoriasis blockbuster Stelara to include the treatment of patients with Crohn's disease.

27th September 2016

Thumbnail

Novartis bags three new approvals for Ilaris

Novartis has picked up three new indications for its anti-inflammatory Ilaris in the US, allowing its use to treat three rare and distinct types of Periodic Fever Syndromes.

27th September 2016

Thumbnail

MSD, Wayra launch new digital accelerator programme

MSD and Wayra UK have unveiled the next focus of their digital health innovation accelerator programme, calling for "radical solutions" to improving the treatment and care of patients with diabetes and helping cancer patients self-manage recovery.

27th September 2016

Thumbnail

Latest SBRI comp offers £1.1m for GP innovations

NHS England investment fund SBRI Healthcare has launched its autumn competition offering entrepreneurs the opportunity for funding to drive forward their innovations within general practice.

26th September 2016

Thumbnail

EU approves Truberzi for IBS-D

European regulators have issued a green light for Allergan's Truberzi, giving patients potential access to the first approved treatment for irritable bowel syndrome with diarrhoea (IBS-D).

23rd September 2016

Thumbnail

Gilead pulls plug on ulcerative colitis drug

Gilead Sciences has pulled the plug on a combined Phase II/III clinical study of GS-5745 testing the investigational anti-MMP9 antibody in patients with moderately to severely active ulcerative colitis.

22nd September 2016

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download